Showing 11 - 20 of 20
Persistent link: https://www.econbiz.de/10014364285
without the patent owner's authorization by issuing a compulsory license (CL). In the pharmaceuticals space, governments have … historically employed compulsory licenses to compel originator manufacturers to license their patents to generic manufacturers … refrain from issuing compulsory licenses. A survey of members' domestic compulsory license legislation finds that virtually …
Persistent link: https://www.econbiz.de/10013469578
the COVID-19 pandemic that are manufactured under a compulsory license or government use authorization to other developing …
Persistent link: https://www.econbiz.de/10013469582
The World Trade Organization (WTO) linked intellectual property protection with trade. The WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement), however, included a number of public health flexibilities in order to provide latitude to the Member States to...
Persistent link: https://www.econbiz.de/10013258010
This paper provides an analysis of patents covering selected antibodies and vaccines used in the treatment or prevention of COVID-19. The aim of the report is to support national patent offices and interested parties in developing countries with information that can serve as guidance for the...
Persistent link: https://www.econbiz.de/10014233696
The major bone of contention between the developed and developing countries in the TRIPS negotiations was patents for pharmaceuticals. The US-led developed countries bloc argued in favour of patents for pharmaceuticals amidst opposition from Brazil, India and other countries. Ample evidence,...
Persistent link: https://www.econbiz.de/10013393634
The COVID-19 crisis intensified decade-long debates on the interaction between intellectual property rights (IPRs), competition law and access to affordable life-saving treatments and vaccines. Compulsory licensing of patented medicines is a tried-and-tested method to expand access, particularly...
Persistent link: https://www.econbiz.de/10014541546
Open source software (OSS) is a public good. A self-interested individual would consider providing such software, if the benefits he gained from having it justified the cost of programming. Nevertheless each agent is tempted to free ride and wait for others to develop the software instead. This...
Persistent link: https://www.econbiz.de/10011436386
Recently the software industry has experienced fundamental changes in market structure through the entry of open source competitors, e.g. Linux's entry into the operating systems market. In a simple model we examine the effects of such a change in market structure from monopoly to duopoly under...
Persistent link: https://www.econbiz.de/10011438863
There is considerable debate regarding the use of intellectual property rights (IPR) to spur innovation in the software industry. In this paper we focus on the choice of intellectual property right regimes and industry growth. We begin by developing a growth optimal mixture of open source and...
Persistent link: https://www.econbiz.de/10003726127